المؤلفون: Betu Kumeso VK; Ministry of Health, Kinshasa, Democratic Republic of the Congo., Kalonji WM; Drugs for Neglected Diseases initiative, Kinshasa, Democratic Republic of the Congo., Rembry S; Drugs for Neglected Diseases initiative, Geneva, Switzerland., Valverde Mordt O; Drugs for Neglected Diseases initiative, Geneva, Switzerland., Ngolo Tete D; Drugs for Neglected Diseases initiative, Kinshasa, Democratic Republic of the Congo., Prêtre A; Drugs for Neglected Diseases initiative, Geneva, Switzerland., Delhomme S; Drugs for Neglected Diseases initiative, Geneva, Switzerland., Ilunga Wa Kyhi M; Dipumba Hospital (MIBA), Mbuji-Mayi, Democratic Republic of the Congo., Camara M; Programme National de Lutte contre la Trypanosomiase Humaine Africaine, Conakry, Guinea., Catusse J; Swiss Tropical and Public Health Institute, Allschwil, Switzerland; University of Basel, Basel, Switzerland., Schneitter S; Swiss Tropical and Public Health Institute, Allschwil, Switzerland; University of Basel, Basel, Switzerland., Nusbaumer M; Swiss Tropical and Public Health Institute, Allschwil, Switzerland; University of Basel, Basel, Switzerland., Mwamba Miaka E; Programme National de Lutte contre la Trypanosomiase Humaine Africaine, Kinshasa, Democratic Republic of the Congo., Mahenzi Mbembo H; Bandundu Hospital, Vanga, Democratic Republic of the Congo., Makaya Mayawula J; Bandundu Hospital, Vanga, Democratic Republic of the Congo., Layba Camara M; HAT treatment centre, Dubreka, Guinea., Akwaso Massa F; Masi Manimba Hospital, Masi-Manimba, Democratic Republic of the Congo., Kaninda Badibabi L; Katanda Hospital, Mbuji-Mayi, Democratic Republic of the Congo., Kasongo Bonama A; Isangi Hospital, Isangi, Democratic Republic of the Congo., Kavunga Lukula P; Bagata Hospital, Bagata, Democratic Republic of the Congo., Mutanda Kalonji S; Drugs for Neglected Diseases initiative, Kinshasa, Democratic Republic of the Congo; Ngandajika Hospital, Kasaï Oriental, Democratic Republic of the Congo., Mariero Philemon P; Programme National de Lutte contre la Trypanosomiase Humaine Africaine, Conakry, Guinea., Mokilifi Nganyonyi R; Kwamouth Hospital, Kwamouth, Democratic Republic of the Congo; Bolobo Hospital, Bolobo, Democratic Republic of the Congo., Embana Mankiara H; Kwamouth Hospital, Kwamouth, Democratic Republic of the Congo., Asuka Akongo Nguba A; Bolobo Hospital, Bolobo, Democratic Republic of the Congo., Kobo Muanza V; Roi Baudoin Hospital, Kinshasa, Democratic Republic of the Congo., Mulenge Nasandhel E; Nkara Hospital, Nkara, Democratic Republic of the Congo., Fifi Nzeza Bambuwu A; Kimpese Hospital, Kimpese, Democratic Republic of the Congo., Scherrer B; Bruno Scherrer Conseil, Saint Arnoult en Yvelines, France., Strub-Wourgaft N; Drugs for Neglected Diseases initiative, Geneva, Switzerland., Tarral A; Drugs for Neglected Diseases initiative, Geneva, Switzerland. Electronic address: atarral@dndi.org.

المصدر: The Lancet. Infectious diseases [Lancet Infect Dis] 2023 Apr; Vol. 23 (4), pp. 463-470. Date of Electronic Publication: 2022 Nov 29.

نوع المنشور: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Science Country of Publication: United States NLM ID: 101130150 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-4457 (Electronic) Linking ISSN: 14733099 NLM ISO Abbreviation: Lancet Infect Dis Subsets: MEDLINE

مواضيع طبية MeSH: Antiprotozoal Agents*/therapeutic use , Trypanosomiasis, African*/drug therapy, Adolescent ; Adult ; Animals ; Female ; Humans ; Male ; Drug Therapy, Combination ; Eflornithine/adverse effects ; Nifurtimox/adverse effects ; Prospective Studies ; Trypanosoma brucei gambiense